Stocks Health care CLRB

NASDAQ · Health care

Cellectar Biosciences, Inc. (CLRB)

It posted a net loss of $22.3M. In fiscal 2025 capital spending exceeded operating cash flow by $23.1M. At June 30, 2026 it held $34M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

What Cellectar Biosciences, Inc. does

Cellectar Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CLRB.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Cellectar Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
2. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
3. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. August 13, 2026
   Passive stake (5% or more) SCHEDULE 13G
6. August 13, 2026
   Quarterly results 8-K
7. August 13, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.57 versus -$3.39.
8. August 4, 2026
   Passive stake (5% or more) SCHEDULE 13G
9. July 10, 2026
   Executive or director change 8-K
10. June 5, 2026
    Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 10, 2026. Insider transactions on SEC

Insider trades

What the people running Cellectar Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CLRB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Hexstone Capital LLC 4.9% (February 4, 2026); ADAR1 Capital Management, LLC 0.1% (August 14, 2025); Nantahala Capital Management, LLC 0.06% (August 14, 2025); Lytton Laurence W 1.6% (August 14, 2025); Mitchell P. Kopin 4.99% (July 8, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CLRB

What does Cellectar Biosciences, Inc. do?

Cellectar Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CLRB.

Is Cellectar Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $22.3M.

When did Cellectar Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 14, 2026.

Similar companies

Compare CLRB with

Compare CLRB with any company

Follow CLRB

Get an email when Cellectar Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CLRB: get an email when it files

Where the numbers come from

Financial figures are the values Cellectar Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.